Compare RCUS & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCUS | NVG |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2018 | N/A |
| Metric | RCUS | NVG |
|---|---|---|
| Price | $21.31 | $12.60 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $29.38 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 568.8K |
| Earning Date | 10-28-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $240,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.50 | $9.68 |
| 52 Week High | $26.40 | $12.21 |
| Indicator | RCUS | NVG |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 48.98 |
| Support Level | $20.35 | $12.65 |
| Resistance Level | $26.10 | $12.79 |
| Average True Range (ATR) | 1.48 | 0.08 |
| MACD | -0.61 | -0.01 |
| Stochastic Oscillator | 15.21 | 28.57 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.